All News

New studies show 2024 IRA Medicare drug caps and expanded subsidies cut cost-related nonadherence, especially for those with chronic disease.

Christopher Shade, PhD, shares insights for managed care leaders on oral peptide therapies.

The incidence of very late onset of myasthenia gravis has increased in the past 50 years, which has had implications on prognosis.

Expert insights reveal how to spot inflammation in deeply pigmented skin and use new biologics and melasma therapies to reduce dyspigmentation.

Experts discuss how CDC opioid guidelines reduced prescribing but led to misapplication, affecting patient care and access to pain treatment.

LLMs may improve pediatric clinical decision-making, but gaps in safety, accuracy, and pediatric-specific data remain.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.

Making health care prices public was supposed to cut costs. The reality is more complicated.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Medicare Advantage enrollees with advanced cancer had higher hospice use than traditional Medicare, highlighting disparities in end-of-life care.

Increased health care costs, use of nonsteroidal immunosuppressants, and elevated health care costs were associated with use of glucocorticoids by patients with myasthenia gravis.

Active or severe atopic dermatitis throughout childhood and adolescence does not increase cardiometabolic risk, according to new research.

March marks the 10th anniversary of the CDC's opioid prescribing guidelines for patients with chronic pain, which were later updated to expand their scope.

Subcutaneous amivantamab offers faster treatment, fewer infusion reactions, and improved convenience for patients with EGFR-mutated NSCLC, says Estelamari Rodriguez, MD, MPH.

Obesity enlarges organs, adding cells that raise liver, kidney, and pancreatic cancer risk, such that organ size may predict danger better than body mass index.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Insulin affordability improved for Medicare Part D beneficiaries between 2019 and 2023, with more paying $35 or less for a 30-day supply.

Smoking cessation, abnormal weight, and socioeconomic deprivation were all associated with mortality in multiple sclerosis.

The standards under this rule will save providers time on paperwork, letting them focus more on patients, says CMS Administrator Mehmet Oz, MD, MBA.

The prevalence of retinal conditions in the US varied by region, race and ethnicity, and sex, which could identify areas of need.

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch block, despite lower costs.

Maria Hordinsky, MD, discusses the promise of Janus kinase (JAK) inhibitors in treating alopecia areata in the long term.

Discussions at this February IVBM evening covered advances in biomarker testing in lung cancer to the real-life challenges of maintaining diversity in clinical trials.

Discussions about drug pricing require consideration of values and preferences, according to Jonathan D. Campbell, PhD, chief science officer of the National Pharmaceutical Council.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.

The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH.

Panelists at a Boston Regional Institute for Value-Based Medicine event examined trial diversity, integrated dispensing, and evolving oncology pathways.

The FDA approved higher-dose semaglutide 7.2 mg (Wegovy HD), marking the fourth drug approved under the Commissioner's National Priority Voucher pilot program.